Spectranetics PELA Study Extended
COLORADO SPRINGS, Jan. 16 -- The Spectranetics Corp. said it has FDA approval to continue its peripheral excimer laser angioplasty (PELA) study, without the need to randomize patients. The study extension, PELA III, allows the excimer laser to be used to treat total occlusions at least 10 cm long of the main thigh artery for 120 additional patients at 21 sites. Patients will be enrolled in PELA III during the follow-up and approval phases of the PELA trial, which completed randomized patient enrollment in November, is on track to receive FDA approval in 2003, Spectranetics said.
LATEST NEWS
- CLEO Heads to the East Coast
Apr 29, 2024
- Laser-Based Gas Analyzer Developed to Detect Air Pollution
Apr 29, 2024
- Qubits Could be Stored in Flash-Like Memory
Apr 29, 2024
- Exail Signs LLNL Contract, Partners with Eelume
Apr 26, 2024
- Menlo Moves U.S. HQ: Week in Brief: 4/26/2024
Apr 26, 2024
- Optofluidics Platform Keys Label-, Amplification-Free Rapid Diagnostic Tool
Apr 25, 2024
- DUV Lasers Made with Nonlinear Crystals Enhance Lithography Performance
Apr 25, 2024
- Teledyne e2v, Airy3D Collaborate on 3D Vision Solutions
Apr 24, 2024